Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood
Late cardiotoxicity is a known complication of anthracycline therapy but the long-term effects of low cumulative doses are not well documented. We studied late cardiotoxicity in survivors of childhood acute lymphoblastic leukemia (ALL) treated with low anthracycline doses 10 to 20 years earlier.
Seventy-seven ALL survivors who received a cumulative anthracycline dose <250 mg/m² and were at least 10 years after treatment were evaluated for signs of clinical heart failure. Cardiac function was assessed by echocardiography including tissue Doppler measurements of the septal mitral annulus in 37 ALL survivors 10.6–18.3 years (median 13.3 years) after anthracycline treatment with cumulative doses of 180 (n = 19) or 240 mg/m² (n = 18). The control group consisted of 30 healthy volunteers matched for age, sex, BSA, and BMI.
No clinical relevant cardiotoxicity was found. Left ventricular shortening fraction (SF) was significantly reduced in male ALL survivors. Three of the 19 male ALL survivors had an SF below 30%. Male ALL survivors showed a significantly lower early filling velocity to atrial contraction velocity ratio but myocardial velocity during early filling was comparable between patients and controls. ALL survivors had a significantly longer isovolumetric relaxation time (IVRT). Thirty percent of the ALL survivors have an abnormal IVRT compared to the normal range of the controls.
Conclusion and implications for cancer survivors
At a median of 13.3 years after exposure to cumulative doses of anthracyclines of 180 or 240 mg/m², no clinical relevant cardiotoxicity was found but subclinical cardiac abnormalities were present in 30% of the patients.
- Goorin AM, Chauvenet AR, Perez-Atayde AR, et al. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr. 1990;116:144–7. CrossRef
- Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–15. CrossRef
- Steinherz LJ, Steinherz P, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672–7. CrossRef
- Sorensen K, Levitt G, Sebag-Montefiore D, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997;15:61–8.
- Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545–50.
- Rammeloo LAJ, Postma A, Soboka-Plojhar MA. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukaemia: no long-term cardiac damage in a randomised study of the Dutch childhood leukaemia study group. Med Ped Oncol. 2000;35:136–9. CrossRef
- De Wolf D, Suys B, Maurus R, et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Res. 1996;39:504–12. CrossRef
- Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart. 2004;90:1214–16. CrossRef
- Suys BE, Katier N, Rooman RP, et al. Female children and adolescents with type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyo-pathy. Diabetes Care. 2004;27:1947–53. CrossRef
- Kapusta L, Thijssen JM, Groot-Loonen J, et al. Tissue Doppler Imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol. 2000;26(7):1099–108. CrossRef
- Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC Report. Children Leukemia Cooperative Group. Leukemia. 2000;14(12):2257–66. CrossRef
- Rowland DG, Gutgesell HP. Use of mean arterial pressure for noninvasive determination of left ventricular end-systolic wall stress in infants and children. Am J Cardiol. 1994;4:98–9. CrossRef
- Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol. 1984;4:1222–30. CrossRef
- Tei C. New noninvasive index for combined systolic and diastolic ventricular function. J Cardiol. 1995;26:135–6.
- Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer. A prospective longitudinal study. Cancer. 2003;97:1991–8. CrossRef
- Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–36. CrossRef
- Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment of childhood cancer. Eur J Pediatr. 2003;162(10):690–6. CrossRef
- Stapleton GE, Stapleton LC, Martinez A, et al. Evaluation of longitudinal ventricular function with tissue Doppler echocardiography in children treated with anthracyclines. J Am Soc Echocardiogr. 2007;20:492–7. CrossRef
- Rathe M, Carlsen NLT, Oxhøj H. Late cardiac effects of anthracycline containing therapy for childhood lymphoblastic leukemia. Pediatr Blood Cancer. 2007;48:663–7. CrossRef
- Ganame J, Cluas P, Uyttebroeck A, et al. Myocardial dysfunction late after low-dose Anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr. 2007;20:1351–8. CrossRef
- Eidem BW, Sapp BG, Suarez CR, et al. Usefulness of the Myocardial Performance Index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol. 2001;87:1120–2. CrossRef
- Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–43. CrossRef
- Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after Adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91:37–44. CrossRef
- van Dalen EC, van der Pal HJ, Kok WE, et al. Clinical heart failure in a cohort af children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006;42:3191–8. CrossRef
- Wouters KA, Kremer LCM, Miller TL, et al. Protecting against anthracycline-induced Myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561–78. CrossRef
- Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94:525–33. CrossRef
- Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the carciovascular disease task force of the Children's Oncology Group. Pediatrics. 2008;121:e387–96. CrossRef
- Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Journal of Cancer Survivorship
Volume 6, Issue 1 , pp 95-101
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Cardiotoxicity after cancer therapy
- Late effects
- Anthracycline-related cardiotoxicity
- Industry Sectors
- Author Affiliations
- 1. Department of Pediatric Hemato-Oncology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium
- 2. Department of Pediatric Cardiology, Ghent University Hospital, Ghent, Belgium